BioCryst Pharmaceuticals | BCRX - 贷款资金



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 1.76B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


贷款资金 更改 日
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Chugai Pharma JPY 4.53B 1.95B 2024-12
Daiichi Sankyo JPY 500B 199.92B 2026-06
DBV Technologies USD 0 0 2025-03
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
Glaxosmithkline GBP 18.53B 1.29B 2026-03
Incyte USD 28.42M 994K 2026-06
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novavax USD 246.3M 200K 2025-12
PTC Therapeutics USD 535.52M 248.58M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12